Morgan Stanley’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-134,401
| Closed | -$2.47M | – | 7694 |
|
|
2020
Q4 | $2.47M | Buy |
134,401
+82,746
| +160% | +$1.51M | ﹤0.01% | 3971 |
|
|
2020
Q3 | $948K | Buy |
51,655
+44,299
| +602% | +$745K | ﹤0.01% | 4243 |
|
|
2020
Q2 | $110K | Buy |
7,356
+3,120
| +74% | +$44.6K | ﹤0.01% | 5364 |
|
|
2020
Q1 | $67K | Sell |
4,236
-15,749
| -79% | -$255K | ﹤0.01% | 5355 |
|
|
2019
Q4 | $325K | Buy |
19,985
+13,188
| +194% | +$220K | ﹤0.01% | 5165 |
|
|
2019
Q3 | $101K | Buy |
6,797
+5,358
| +372% | +$72.2K | ﹤0.01% | 5446 |
|
|
2019
Q2 | $23K | Sell |
1,439
-1,796
| -56% | -$29.3K | ﹤0.01% | 5894 |
|
|
2019
Q1 | $55K | Sell |
3,235
-16,806
| -84% | -$305K | ﹤0.01% | 5625 |
|
|
2018
Q4 | $354K | Sell |
20,041
-250
| -1% | -$4.25K | ﹤0.01% | 5011 |
|
|
2018
Q3 | $369K | Sell |
20,291
-5,797
| -22% | -$119K | ﹤0.01% | 5154 |
|
|
2018
Q2 | $510K | Buy |
26,088
+10,850
| +71% | +$203K | ﹤0.01% | 5088 |
|
|
2018
Q1 | $267K | Buy |
15,238
+13,938
| +1,072% | +$255K | ﹤0.01% | 5348 |
|
|
2017
Q4 | $15K | Hold |
1,300
| – | – | ﹤0.01% | 6152 |
|
|
2017
Q3 | $14K | Sell |
1,300
-4,997
| -79% | -$47.3K | ﹤0.01% | 6116 |
|
|
2017
Q2 | $55K | Sell |
6,297
-10,974
| -64% | -$96.7K | ﹤0.01% | 5826 |
|
|
2017
Q1 | $203K | Sell |
17,271
-19,421
| -53% | -$236K | ﹤0.01% | 5326 |
|
|
2016
Q4 | $481K | Buy |
36,692
+34,468
| +1,550% | +$461K | ﹤0.01% | 4956 |
|
|
2016
Q3 | $32K | Buy |
2,224
+2,174
| +4,348% | +$30.9K | ﹤0.01% | 5762 |
|
|
2016
Q2 | $1K | Sell |
50
-46
| -48% | -$739 | ﹤0.01% | 6461 |
|
|
2016
Q1 | $2K | Sell |
96
-108
| -53% | -$1.79K | ﹤0.01% | 6422 |
|
|
2015
Q4 | $4K | Sell |
204
-1,059
| -84% | -$22.4K | ﹤0.01% | 6427 |
|
|
2015
Q3 | $21K | Buy |
1,263
+473
| +60% | +$11.8K | ﹤0.01% | 6042 |
|
|
2015
Q2 | $30K | Sell |
790
-5,539
| -88% | -$179K | ﹤0.01% | 6026 |
|
|
2015
Q1 | $199K | Buy |
6,329
+6,296
| +19,079% | +$170K | ﹤0.01% | 5208 |
|
|
2014
Q4 | $0 | Sell |
33
-3,131
| -99% | -$47.9K | ﹤0.01% | 6733 |
|
|
2014
Q3 | $66K | Buy |
+3,164
| New | +$64.5K | ﹤0.01% | 5634 |
|
Morgan Stanley's CBMG Position: Q1 2021 in Review
Morgan Stanley sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 134,401 shares — an estimated $2.47M sold.
Morgan Stanley first reported a position in CBMG in Q3 2014 and held it in 26 quarters. The position peaked at $2.47M in Q4 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Morgan Stanley reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Morgan Stanley sold 134,401 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $2.47M.
- Morgan Stanley first reported a position in Cellular Biomedicine Group, Inc. in Q3 2014 and held it in 26 quarters.
- Morgan Stanley's Cellular Biomedicine Group, Inc. position peaked at $2.47M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Morgan Stanley's 13F filing for Q1 2021, filed 17 May 2021.